Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OBIO vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Captures Overall Composite Edge (34.3 SELL vs 42.9 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars
ATYR Overall Winner
6-Pillar Tally: OBIO 3 – 2 ATYR (1 Tie)
Matrix Metrics: OBIO 4 – 4 ATYR
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.07 (N/M Forward P/E, -195.4% operating margin) versus ATYR at $4.96 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OBIO vs ATYR
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
$7.07
-0.7% 1D
Market Cap
$570.6M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.15β · 80% Vol
Unified Composite Score
42.9
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.96
-5.34% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.67β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 ATYR)
1. Valuation Multiples
OBIO
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
18.6x
N/M
2. Growth & Scale
OBIO
Revenue Growth (YoY)
-89.4%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
N/A
Market Cap
$570.6M
$15.6M
3. Profitability & Quality
ATYR
Gross Margin
99.6%
N/A
Operating Margin
-195.4%
0.0%
Net Profit Margin
-182.5%
0.0%
Return on Equity (ROE)
-182.3%
-93.7%
4. Balance Sheet & Cash Flow
ATYR
Cash Generation (TTM)
-$64M
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$9.0M Net Debt (4.72x D/E)
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
70.8% (<1st %ile)
154.5% (36th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OBIO (4) vs ATYR (4)| Institutional Metric | OBIO | ATYR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $570.6M | $15.6M | OBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -89.4% | +0.0% | ATYR | |
| Operating Margin (TTM) | -195.4% | 0.0% | ATYR | |
| Net Profit Margin | -182.5% | 0.0% | ATYR | |
| Return on Equity (ROE) | -182.3% | -93.7% | ATYR | |
| 52-Week Range Position | 90% ($3–$7) | 62% ($0–$8) | OBIO | |
| Beta / 30D Volatility | 1.15β · 80% Vol | -9.67β · 13806% Vol | OBIO | |
| Unified Institutional Score | 42.9 / 100 (HOLD) | 34.3 / 100 (SELL) | OBIO | |
| Trailing 12M Revenue (USD) | $31M | N/A | Scale | |
| Gross Profit Margin (TTM) | 99.6% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 18.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($9.0M Net Debt (4.72x D/E)) | N/A ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2763.63 pp
3M Horizon
ATYR +803.54 pp
6M Horizon
ATYR +850.17 pp
1Y Horizon
ATYR +479.26 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | ATYR Revenue | OBIO Op. Margin | ATYR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -5445.0% | ATYR |
| FY2020 | N/A | $10M | N/A | -152.2% | ATYR |
| FY2022 | $0M | $10M | -924.3% | -446.8% | ATYR |
| FY2023 | $0M | $0M | -1866.2% | -15557.8% | OBIO |
| FY2024 | $0M | $0M | -2437.5% | -28899.6% | OBIO |
| FY2025 | $30M | $0M | -154.7% | -40856.3% | OBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OBIO
BREAKOUT
Current IV
70.8%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OBIO vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.07 (N/M Forward P/E, -195.4% operating margin) versus ATYR at $4.96 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), OBIO cumulative revenue shifted N/A while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
OBIO screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ATYR vs OBIO · Reverse Pair
OBIO vs OABI
· Sector Peer
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking